These results indicate that the release of other factors from the HDIL-2-induced inflammation could trigger the expression of FoxO1 in the tumor, and such factors work together with resveratrol co-treatment to further enhance the expression of FoxO1. This evidence concerns the gene FOXO1 and neoplasm.